Editorial

CARの扉を開くカギ

Nature Biotechnology 35, 10 doi: 10.1038/nbt.3993

Although Kymriah's approval represents a landmark for chimeric antigen receptor T-cell (CAR-T) therapy in B-cell malignancies, solid tumors remain a formidable challenge.

目次へ戻る

プライバシーマーク制度